Fig 1.
Patient selection flow diagram.
MRI; Magnetic Resonance Imaging, DRE; Digital Rectal Exam.
Table 1.
Clinicopathological characteristics of patients with unilateral prostatic lobe not suspected to harbor PCa by the combination of TRUS biopsy and mpMRI.
Table 2.
Pathological outcome of unilateral lobe not suspected to harbor PCa by the combination of TRUS biopsy and mpMRI.
Table 3.
Comparison of pathological outcomes of unilateral lobe not suspected to harbor PCa by the combination of TRUS biopsy and mpMRI between D’Amico low risk group and D’Amico intermediate to high risk group.
Table 4.
Absence rates of significant cancer, unfavorable disease, and dominant Gleason pattern ≥ 4 according to the subgroups.
Table 5.
Sensitivity analysis outcome of the combination of TRUS biopsy and mpMRI (positive biopsy core or PI-RAD≥3 lesion) to detect malignancy, significant cancer, and unfavorable pathology of each prostate lobe (670 lobes) among study cohort (n = 335).